Revvity Reports Q2 2026 Results; Probable Sale of China IDX for up to $200M

What Happened
Revvity, Inc. (RVTY) filed a Form 8-K on August 4, 2026 reporting its financial results for the second quarter ended July 5, 2026 (press release furnished as Exhibit 99.1). The company also disclosed (Item 8.01) a definitive agreement signed July 31, 2026 to sell substantially all assets of its China Immunodiagnostics business (“China IDX”). Management considers the sale probable and provided unaudited pro forma condensed consolidated financial statements to reflect the transaction (Exhibit 99.2).

Key Details

• Agreement signed: July 31, 2026.
• Consideration: up to $200 million, subject to adjustments and conditions.
• Timing: Company believes closing is probable by the end of 2027 and included pro forma financials accordingly.
• Filings: Q2 results press release is Exhibit 99.1; unaudited pro forma condensed consolidated financial statements are Exhibit 99.2 to the 8-K.

Why It Matters
The announced sale would divest Revvity’s China immunodiagnostics assets and could meaningfully affect the company’s future revenue mix and reported results; the company has provided pro forma financials so investors can see the potential impact. Because the transaction is classified as probable but not closed, investors should note there are conditions and adjustments that could change the final proceeds and timing. The filing also includes standard forward-looking statement cautions about risks and uncertainties.